Avraham initiates ladostigil Stage 2 trial in MCI Avraham Pharmaceuticals Ltd zydena fiyat? . Today the commencement of a Stage announced 2 clinical trial to judge the basic safety and efficacy of ladostigil in patients diagnosed with moderate cognitive impairment . This 36-month, multi-center, randomized, double-blind, placebo-controlled trial shall include at least 200 sufferers in 16 centers in Israel and Europe. The Phase 2 research is a double-blind, closed-label, placebo-controlled trial occurring at 20 sites in five countries across European countries.